首页> 美国卫生研究院文献>Clinical and Translational Science >The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)‐Endoxifen in Breast Cancer

【2h】

The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)‐Endoxifen in Breast Cancer

机译：坚持他莫昔芬和CYP2D6药物遗传学对乳腺癌中活性代谢物（Z）-内氧芬的血浆浓度的影响

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 Clinical and Translational Science
作者
Jeanine Marie Nardin; Werner Schroth; Thais Abreu Almeida; Thomas Mürdter; Solane Picolotto; Evelyn Castillo Lima Vendramini; Reiner Hoppe; Jenifer Primon Kogin; Diandra Miqueleto; Silvia Dark Robaskievicz de Moraes; Matthias Schwab; Roberto Flavio Pecoits‐Filho; Hiltrud Brauch; José Claudio Casali‐da‐Rocha;
展开▼
作者单位

展开▼
年(卷),期 2020(13),2
年度 2020
页码 -1
总页数 9
原文格式 PDF
正文语种
中图分类医学史;
关键词

相似文献

外文文献
中文文献
专利

1. The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)-Endoxifen in Breast Cancer [J] . Industrial and organizational psychology . 2020,第2期

机译：在乳腺癌中，粘附对Tamoxifen和Cym2D6药物obsegens血浆浓度的影响
2. The influences of adherence to tamoxifen and CYP2D6 pharmacogenetics on plasma concentrations of the active metabolite (Z)-endoxifen in breast cancer [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：在乳腺癌中，粘附对Tamoxifen和Cym2D6药物obsegens血浆浓度的影响
3. Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score. [J] . Barginear MF, Jaremko M, Peter I, Clinical Pharmacology and Therapeutics . 2011,第4期

机译：基于CYP2D6基因型和内皮西芬水平的乳腺癌患者中他莫昔芬剂量的增加：对活性代谢物异构体和抗雌激素活性评分的影响。
4. Study on Molecular Docking of Red Betel (Piper Crocatum Ruiz Pav.) Active Compound and Tamoxifen Drug as an Inhibitor of Estrogen Receptor-α (ER-α) that Plays a Role in Breast Cancer [C] . Siti Imroatul Maslikah, Sri Rahayu Lestari, Nursasi Handayani, International Conference on Life Sciences and Technology . 2020

机译：红色槟榔（吹笛茶叶ruiz＆pav.）活性化合物和三氧化物药物作为发挥乳腺癌作用的雌激素受体-α（ER-α）抑制剂的研究
5. Tamoxifen use, adherence to therapy, and quality of life in older breast cancer patients. [D] . Newell, Debra Ann. 2003

机译：他莫昔芬的使用，对治疗的依从性以及老年乳腺癌患者的生活质量。
6. CYP2D6 Genotype Predicts Plasma Concentrations of Tamoxifen Metabolites in Ethiopian Breast Cancer Patients [O] . Jemal Hussien Ahmed, Eyasu Makonnen, Alan Fotoohi, 2019

机译：CYP2D6基因型预测埃塞俄比亚乳腺癌患者中他莫昔芬代谢物的血浆浓度
7. Are plasma concentrations of tamoxifen active metabolites sufficient to ensure therapeutic efficacy for tamoxifen treated women with breast cancer in Poland? [O] . Ewa E. Hennig 2016

机译：是三莫昔芬活性代谢物的血浆浓度，足以确保波兰乳腺癌患有乳腺癌的治疗性疗效？
8. Systematic Reviews on Selected Pharmacogenetic Tests for Cancer Treatment: CYP2D6 for Tamoxifen in Breast Cancer, KRAS for anti-EGFR antibodies in Colorectal Cancer, and BCR-ABL1 for Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. Technology Assessment Report [R] . Terasawa, T., Dahabreh, I., Castaldi, P. J., 2010

机译：针对癌症治疗的选定药物遗传学测试的系统评价：CYp2D6用于乳腺癌中的他莫昔芬，KRas用于结肠直肠癌中的抗EGFR抗体，以及BCR-aBL1用于慢性髓性白血病中的酪氨酸激酶抑制剂。技术评估报告

The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)‐Endoxifen in Breast Cancer

著录项

相似文献

相关主题

期刊订阅